<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29601" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Subacute Necrotizing Encephalomyelopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fecek</surname>
            <given-names>Christopher</given-names>
          </name>
          <aff>Peconic Bay Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Samanta</surname>
            <given-names>Debopam</given-names>
          </name>
          <aff>University of Arkansas for Medical Sciences</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Christopher Fecek declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Debopam Samanta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29601.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Subacute necrotizing encephalomyelopathy (SNE) is primarily a disease of childhood that affects the central nervous system. This is a rare condition that is passed on through nuclear, X-linked, and mtDNA inheritance patterns. This activity outlines the evaluation and management of and highlights the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the etiology of subacute necrotizing encephalomyelopathy.</p></list-item><list-item><p>Explain management options for patients with subacute necrotizing encephalomyelopathy.</p></list-item><list-item><p>Outline the typical presentation of a patient with subacute necrotizing encephalomyelopathy.</p></list-item><list-item><p>Describe interprofessional team strategies for improving care coordination and communication to advance the care of patients with subacute necrotizing encephalomyelopathy and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29601&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29601">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29601.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Subacute necrotizing encephalomyelopathy (SNE), also known as Leigh syndrome, is a&#x000a0;genetically heterogeneous disease that primarily affects the central nervous system. Originally characterized in 1951, the syndrome&#x000a0;is characterized by&#x000a0;focal and bilaterally symmetrical,&#x000a0;necrotic&#x000a0;lesions involving&#x000a0;the thalamus, brainstem, and posterior columns of the spinal cord.<xref ref-type="bibr" rid="article-29601.r1">[1]</xref></p>
      </sec>
      <sec id="article-29601.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>ATP is the primary energy currency in human cells. The production of this energy&#x000a0;currency is mandated by the flux of hydrogen ions down a concentration gradient. This gradient is maintained by mitochondrial respiratory chain complexes during the process of oxidative phosphorylation.<xref ref-type="bibr" rid="article-29601.r2">[2]</xref>&#x000a0;In subacute necrotizing encephalomyelopathy, mutations in mitochondrial respiratory chain complexes lead to the disruption of ATP synthesis. It is this disruption of ATP synthesis that leads to the characteristic pathology of SNE. SNE is genetically heterogeneous since mutations can appear at any point in the mitochondrial respiratory chain. Pathologic mutations have been identified in over 85 different genes that have been shown to be inherited via autosomal, X-linked, or mtDNA patterns.<xref ref-type="bibr" rid="article-29601.r3">[3]</xref><xref ref-type="bibr" rid="article-29601.r4">[4]</xref><xref ref-type="bibr" rid="article-29601.r5">[5]</xref></p>
      </sec>
      <sec id="article-29601.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Subacute necrotizing encephalomyelopathy is primarily a disease of infancy, typically first becoming clinically evident between three and 12 months of age. SNE occurring later in life have been seen, but adult-onset cases are rare.<xref ref-type="bibr" rid="article-29601.r6">[6]</xref>&#x000a0;The incidence of the disease is affected by the type of inheritance pattern. Disease&#x000a0;resulting from genes encoded in the cell nucleus&#x000a0;has an incidence of approximately 1 in 40,000 live births.<xref ref-type="bibr" rid="article-29601.r7">[7]</xref>&#x000a0;However, the mitochondrial inheritance pattern in much rarer, affecting roughly 1 in 100,000 to 1 in 140,000&#x000a0;newborns. SNE has also been shown to have a predilection towards certain populations. In a region between Norway and Iceland, on the Faroe Islands, SNE incidence increases to 1 in 1,700 births, while 1 in 2,000 newborns are affected in&#x000a0;Quebec, Canada, specifically the Lac-Saint-Jean region.<xref ref-type="bibr" rid="article-29601.r7">[7]</xref><xref ref-type="bibr" rid="article-29601.r8">[8]</xref>&#x000a0;Current data suggests earlier disease onset in patients harboring mutations in nuclear DNA compared to mitochondrial DNA.<xref ref-type="bibr" rid="article-29601.r1">[1]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-29601.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The history and physical exam findings of patients with subacute necrotizing encephalomyelopathy manifest primarily in neuromuscular fashion. Developmental&#x000a0;delay or regression is the most common finding in over 50% of patients. Affected individuals demonstrate motor delay, progressive cognitive decline, dystonia, ataxia, and brainstem dysfunction. Epileptic seizures and respiratory dysfunction are found in approximately 33% and 34% of cases, respectively.<xref ref-type="bibr" rid="article-29601.r1">[1]</xref>&#x000a0;Other clinical manifestations are weakness, fatigue, hypotonia, tremor, poor sucking and feeding, ptosis, nystagmus, abnormal ocular findings,&#x000a0;and failure to thrive. The most common cardiac abnormalities are&#x000a0;hypertrophic cardiomyopathy, followed by arrhythmia and dilated cardiomyopathy. Due to SNE's high mortality rate early in life, a family history of affected individuals is frequently not able to be ascertained. Occasionally, the mitochondrial DNA variant of the disease is present in only a small portion of maternal mitochondrial DNA. In these rare cases, the mother of a proband may have mild symptoms later in life or remains asymptomatic.</p>
      </sec>
      <sec id="article-29601.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Subacute necrotizing encephalomyelopathy demonstrates a wide array of laboratory, molecular, and radiographic findings. While there are no established diagnostic criteria, affected individuals often share key features. A recent meta-analysis demonstrated that the lactate levels in the blood and CSF of affected patients are elevated in up to 72% of patients. On a molecular level, 80% of SNE cases&#x000a0;lack a complete mitochondrial respiratory chain enzyme complex with DNA mutations of the mitochondria (32%) and cell nucleus (38%).<xref ref-type="bibr" rid="article-29601.r1">[1]</xref>&#x000a0;Symmetric CNS lesions are the hallmark of imaging studies for SNE. CT and MRI imaging commonly reveal lesions affecting the spinal cord, basal ganglia, cerebellum, diencephalon, and brainstem.&#x000a0;Radiographic T1-weighted MRI and CT images&#x000a0;show a hypointense signal, while T2-weighted MRI images are hyperintense.<xref ref-type="bibr" rid="article-29601.r1">[1]</xref>&#x000a0;Besides nonspecific degenerative changes in the muscle, the transmission electron microscope may reveal sarcoplasmic accumulation in both normal and abnormal mitochondrial morphology or large/swollen mitochondria with or without abnormal cristae.</p>
      </sec>
      <sec id="article-29601.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Currently, there is no cure for subacute necrotizing encephalomyelopathy. Treatment strategies depend on the mode of inheritance and include both correcting underlying metabolic disturbances and supportive care. Supportive care targets mainly acidosis, seizures, and dystonias. Acute exacerbations of acidosis can be treated with either sodium bicarbonate or sodium citrate.<xref ref-type="bibr" rid="article-29601.r7">[7]</xref>&#x000a0;Antiseizure medication can be tailored based on seizure type but should exclude sodium valproate and barbituates, due to their negative effect on the mitochondrial respiratory chain.<xref ref-type="bibr" rid="article-29601.r9">[9]</xref>&#x000a0;Finally, dystonias can be managed as single-agent therapy or combination therapy with benzhexol, baclofen, tetrabenazine, and gabapentin. In refractory cases of dystonia, botulinum toxic injections can also be considered.<xref ref-type="bibr" rid="article-29601.r7">[7]</xref>&#x000a0;In SNE cases where nuclear DNA is involved, treatment is based on the subtype. For instance, in the case of thiamine transporter-2 and biotinidase deficiency, patients have responded well to lifelong treatment with a combination of&#x000a0;thiamine and biotin&#x000a0;or biotin therapy alone, respectively. Furthermore, coenzyme Q10 biosynthesis deficiency shows a positive response to coenzyme Q10 supplementation.<xref ref-type="bibr" rid="article-29601.r10">[10]</xref>&#x000a0;Novel therapies for SNE are also on the rise. An open-label phase 2A trial conducted in 2012 evaluated&#x000a0;the use of a novel therapeutic agent,&#x000a0;EPI-743, in pediatric cases of SNE. The results demonstrated statistically significant improvement and reversal in disease progression, compared to untreated children.<xref ref-type="bibr" rid="article-29601.r11">[11]</xref></p>
      </sec>
      <sec id="article-29601.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Many diseases can mimic subacute necrotizing encephalomyelopathy. It is, therefore, important to build a&#x000a0;broad differential diagnosis during work-up. Several diseases affecting the mitochondria can mimic both nuclear DNA and mt-DNA variants, including mitochondrial depletion syndrome, mitochondrial translation defect, and MEGDEL syndrome.<xref ref-type="bibr" rid="article-29601.r7">[7]</xref></p>
      </sec>
      <sec id="article-29601.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of subacute necrotizing encephalomyelopathy is poor. The median age at death is just over 2 years, with the main cause of death is respiratory complications. Respiratory and heart failure have been shown to cause mortality in&#x000a0;50% of affected individuals by the age of three.<xref ref-type="bibr" rid="article-29601.r7">[7]</xref>&#x000a0;Similar to other mitochondrial diseases, SNE also demonstrates a median survival of approximately 90 days.<xref ref-type="bibr" rid="article-29601.r12">[12]</xref>&#x000a0;Disease onset prior to 6 months of age, failure to thrive, brainstem lesions, and intensive care unit (ICU) admissions have been associated with poor survival. Though the adult-onset disease is rare, affected individuals are thought to have a less severe form of the disease.<xref ref-type="bibr" rid="article-29601.r13">[13]</xref></p>
      </sec>
      <sec id="article-29601.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Most complications from subacute necrotizing encephalomyelopathy are related to the central and peripheral nervous system and include deafness, retinitis&#x000a0;pigmentosa, developmental delay, and dysphagia.<xref ref-type="bibr" rid="article-29601.r14">[14]</xref>&#x000a0;Nervous system deficits may extend into the peripheral nervous system to include polyneuropathy and myopathy. Less frequently, non-nervous system organs are affected, and SNE individuals may develop hypertrophic cardiomyopathy and hormonal imbalances.<xref ref-type="bibr" rid="article-29601.r14">[14]</xref></p>
      </sec>
      <sec id="article-29601.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Due to the high mortality and rarity of SNE, mothers, and fathers of affected individuals must be screened for any genetic abnormalities. In addition, the risk of having additional children should be discussed with each family. Once the disease has manifested, it is imperative to diagnose the disease subtype, since this can affect both the course and efficacy of treatment.<xref ref-type="bibr" rid="article-29601.r10">[10]</xref></p>
      </sec>
      <sec id="article-29601.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Subacute necrotizing encephalomyelopathy is a multifactorial disease, affecting many different organ systems in the body. Information sharing of&#x000a0;evidence-based medical research and collaborative care has&#x000a0;proven both pragmatic and cost-effective at improving patient outcomes.[Level 1]<xref ref-type="bibr" rid="article-29601.r15">[15]</xref>&#x000a0;The potential to improve morbidity and mortality in SNE, therefore, lies in physicians' abilities to disseminate new information regarding best practices.[Level 1]<xref ref-type="bibr" rid="article-29601.r16">[16]</xref>&#x000a0;In addition to working together, it is also essential the interprofessional team&#x000a0;come to agreements on the final message being sent to the patient.<xref ref-type="bibr" rid="article-29601.r17">[17]</xref>&#x000a0;This can include primary care providers, neurologists, palliative care, pharmacists, and specialty trained nurses. A 2012 qualitative study found that, due to a perceived divide amongst health care professionals in different fields, patients received more mixed messages from providers.</p>
        <p>The potential for such a phenomenon to negatively impact patient care cannot be ignored. Providers must reach out to other specialties of medicine when feelings of incomplete knowledge on a disease or organ system arise.<xref ref-type="bibr" rid="article-29601.r17">[17]</xref>[Level 5] Due to high mortality, end of life palliative care is the final critical step in a patient affected with SNE. By informing patients and their families about end of life and palliative care comfort options,&#x000a0;unnecessary suffering is avoided both in the patient and their caregivers.[Level 2]<xref ref-type="bibr" rid="article-29601.r18">[18]</xref></p>
      </sec>
      <sec id="article-29601.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29601&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29601">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/subacute-necrotizing-encephalomyelopathy-leigh-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29601">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29601/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29601">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29601.s14">
        <title>References</title>
        <ref id="article-29601.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A meta-analysis and systematic review of Leigh syndrome: clinical manifestations, respiratory chain enzyme complex deficiency, and gene mutations.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>99</volume>
            <issue>5</issue>
            <fpage>e18634</fpage>
            <pub-id pub-id-type="pmid">32000367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sousa</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>D'Imprima</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vonck</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Mitochondrial Respiratory Chain Complexes.</article-title>
            <source>Subcell Biochem</source>
            <year>2018</year>
            <volume>87</volume>
            <fpage>167</fpage>
            <page-range>167-227</page-range>
            <pub-id pub-id-type="pmid">29464561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lake</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Compton</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thorburn</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Leigh syndrome: One disorder, more than 75 monogenic causes.</article-title>
            <source>Ann Neurol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>190</fpage>
            <page-range>190-203</page-range>
            <pub-id pub-id-type="pmid">26506407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Noronha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Leigh map: A novel computational diagnostic resource for mitochondrial disease.</article-title>
            <source>Ann Neurol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-16</page-range>
            <pub-id pub-id-type="pmid">27977873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Martikainen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Gorman</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Blain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bugiardini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bunting</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Alston</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Blakely</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Goede</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McEntagart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Spinty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Horrocks</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Chinnery</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Horvath</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nesbitt</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fratter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Poulton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Pitceathly</surname>
                <given-names>RDS</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Turnbull</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>McFarland</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pathogenic variants in MT-ATP6: A United Kingdom-based mitochondrial disease cohort study.</article-title>
            <source>Ann Neurol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>86</volume>
            <issue>2</issue>
            <fpage>310</fpage>
            <page-range>310-315</page-range>
            <pub-id pub-id-type="pmid">31187502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rahman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thorburn</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Nuclear Gene-Encoded Leigh Syndrome Spectrum Overview</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2015</year>
            <month>10</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">26425749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ball</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thorburn</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Mitochondrial DNA-Associated Leigh Syndrome Spectrum</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Adam</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mirzaa</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pagon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Amemiya</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source>
            <publisher-name>University of Washington, Seattle</publisher-name>
            <publisher-loc>Seattle (WA)</publisher-loc>
            <year>2003</year>
            <month>10</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">20301352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruhoy</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Saneto</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>The genetics of Leigh syndrome and its implications for clinical practice and risk management.</article-title>
            <source>Appl Clin Genet</source>
            <year>2014</year>
            <volume>7</volume>
            <fpage>221</fpage>
            <page-range>221-34</page-range>
            <pub-id pub-id-type="pmid">25419155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Norquist</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Vesce</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nicholls</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Soine</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Duan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Barbiturates induce mitochondrial depolarization and potentiate excitotoxic neuronal death.</article-title>
            <source>J Neurosci</source>
            <year>2002</year>
            <month>Nov</month>
            <day>01</day>
            <volume>22</volume>
            <issue>21</issue>
            <fpage>9203</fpage>
            <page-range>9203-9</page-range>
            <pub-id pub-id-type="pmid">12417645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanabus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heales</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Development of pharmacological strategies for mitochondrial disorders.</article-title>
            <source>Br J Pharmacol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>171</volume>
            <issue>8</issue>
            <fpage>1798</fpage>
            <page-range>1798-817</page-range>
            <pub-id pub-id-type="pmid">24116962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinelli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Catteruccia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piemonte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pastore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tozzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dionisi-Vici</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pontrelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corsetti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Livadiotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kheifets</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hinman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shrader</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Thoolen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Bertini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>EPI-743 reverses the progression of the pediatric mitochondrial disease--genetically defined Leigh Syndrome.</article-title>
            <source>Mol Genet Metab</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>107</volume>
            <issue>3</issue>
            <fpage>383</fpage>
            <page-range>383-8</page-range>
            <pub-id pub-id-type="pmid">23010433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-Cazorla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Lonlay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nassogne</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rustin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Touati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saudubray</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Long-term follow-up of neonatal mitochondrial cytopathies: a study of 57 patients.</article-title>
            <source>Pediatrics</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>116</volume>
            <issue>5</issue>
            <fpage>1170</fpage>
            <page-range>1170-7</page-range>
            <pub-id pub-id-type="pmid">16264005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Piligian</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Chason</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Adult form of subactute necrotizing encephalomyelopathy.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>1979</year>
            <month>Jul</month>
            <volume>103</volume>
            <issue>7</issue>
            <fpage>344</fpage>
            <page-range>344-7</page-range>
            <pub-id pub-id-type="pmid">582278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finsterer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Leigh and Leigh-like syndrome in children and adults.</article-title>
            <source>Pediatr Neurol</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>223</fpage>
            <page-range>223-35</page-range>
            <pub-id pub-id-type="pmid">18805359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Celano</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Healy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Mastromauro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Huffman</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Cost-Effectiveness of a Collaborative Care Depression and Anxiety Treatment Program in Patients with Acute Cardiac Illness.</article-title>
            <source>Value Health</source>
            <year>2016</year>
            <season>Mar-Apr</season>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>185</fpage>
            <page-range>185-91</page-range>
            <pub-id pub-id-type="pmid">27021752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parikh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Biondi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nazif</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wasif</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Nichols</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ralston</surname>
                <given-names>S</given-names>
              </name>
              <collab>Value in Inpatient Pediatrics Network Quality Collaborative For Improving Care In Community Acquired Pneumonia</collab>
            </person-group>
            <article-title>A Multicenter Collaborative to Improve Care of Community Acquired Pneumonia in Hospitalized Children.</article-title>
            <source>Pediatrics</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>139</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">28148730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bissett</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Preshaw</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Presseau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rapley</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>A qualitative study exploring strategies to improve the inter-professional management of diabetes and periodontitis.</article-title>
            <source>Prim Care Diabetes</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-132</page-range>
            <pub-id pub-id-type="pmid">31831377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29601.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piamjariyakul</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Petitte</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Smothers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morrissey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sokos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Study protocol of coaching end-of-life palliative care for advanced heart failure patients and their family caregivers in rural appalachia: a randomized controlled trial.</article-title>
            <source>BMC Palliat Care</source>
            <year>2019</year>
            <month>Dec</month>
            <day>29</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>119</fpage>
            <pub-id pub-id-type="pmid">31884945</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
